Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We have screened sporadic early-onset Alzheimer's disease (sEOAD, n = 408) samples using the NeuroX array for known causative and predicted pathogenic variants in 16 genes linked to familial forms of neurodegeneration. We found 2 sEOAD individuals harboring a known causative variant in PARK2 known to cause early-onset Parkinson's disease; p.T240M (n = 1) and p.Q34fs delAG (n = 1). In addition, we identified 3 sEOAD individuals harboring a predicted pathogenic variant in MAPT (p.A469T), which has previously been associated with AD. It is currently unknown if these variants affect susceptibility to sEOAD, further studies would be needed to establish this. This work highlights the need to screen sEOAD individuals for variants that are more classically attributed to other forms of neurodegeneration.

Original publication




Journal article


Neurobiol Aging

Publication Date





215.e1 - 215.e8


Alzheimer's disease, Early-onset, NeuroX, Parkinson's disease, Screening, Sporadic, Alzheimer Disease, DNA Mutational Analysis, Genetic Association Studies, Genetic Predisposition to Disease, Genetic Testing, Genetic Variation, Humans, Oligonucleotide Array Sequence Analysis, Parkinson Disease, Ubiquitin-Protein Ligases, tau Proteins